Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


13. July 2021 | 07:55 CET

BioNTech, Defence Therapeutics, Formycon - Which biotech stock suits which investor?

  • Biotechnology
Photo credits: pixabay.com

Corona is and remains the threat of the hour. In this respect, it is not surprising that the papers of the German vaccine pioneer BioNTech have gone on a fabulous journey. Other companies are still trying to jump on this bandwagon, too. For example, both Canada's Defence Therapeutics and Munich-based Formycon AG are researching a Covid-19 vaccine. However, these developments are at very different stages. In addition, the further product spectrum differs significantly in some cases. But which share is the right one for the portfolio? We took a closer look at the three dissimilar siblings.

time to read: 4 minutes by Carsten Mainitz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013 , FORMYCON AG | DE000A1EWVY8


 

Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author


BioNTech SE - Application to FDA for approval of a third "booster vaccine" likely to expand revenues further

The positive newsflow at BioNTech does not stop. Protection of the human body after vaccination has proven to be highly robust, even against the various mutations up to the Delta variant of the SARS-CoV-2 virus. However, the Company has now conceded that the protective effect will likely diminish after about half a year. Data from the Israeli Ministry of Health had indicated this. However, what initially sounds like a negative headline opens up great business potential on the other side. According to the Company, vaccination protection can be restored or even improved by a third booster shot.

Consequently, the Company, together with technology partner Pfizer, has applied to the US Food & Drug Administration (FDA) for approval of the booster shot. Inquiries with the European Medicines Agency (EMA) and other relevant agencies worldwide are expected to follow. In a joint statement with the US Food and Drug Administration (CDC), the FDA initially rejected the third dose for Americans who had previously been fully vaccinated. However, the FDA made it clear that the issue was currently being investigated, and this recommendation could, of course, be revised at any time in the event of new findings.

According to BioNTech/Pfizer, this will happen soon, so production of the additional vaccine doses could begin very soon. In this context, they also plan to develop a version of the common mRNA vaccine that is better adapted to the new mutations. All of this is fantastic news for existing BioNTech shareholders. Investors who have not yet invested may prefer to pause. Analysts have set their price target at around EUR 150, which would be an upside potential of around 20%.

Defence Therapeutics - Canadian ADC pioneers report success in the fight against Covid-19

The Canadian biotechnology Company Defence Therapeutics is developing the next generation of vaccines and ADC preparations (ADC = Antibody Drug Conjugates, i.e. the antibody-drug combination in a "piggyback" process) based on its proprietary Accum platform. This process, which is considered particularly promising for cancer therapy, is similar to the mRNA process used by BioNTech in its Covid-19 vaccine. Defence is also currently researching such a process. A few days ago, the Company announced a great success: serum isolated from animals vaccinated with the AccuVAC-PT001 vaccine developed by Defence showed cross-reactions with the spike protein of several SARS-CoV-2 variants in laboratory tests.

The highest efficacy was observed with the currently rampant Delta variant. The vaccine was effective in blocking infection of the parent strain. Further laboratory tests are now underway to verify the neutralization ability of the antibodies produced. The long-term goal is to develop a booster vaccine that blocks both virus transmission and immune evasion by means of further mutation. But Defence Therapeutics is also continuing full steam ahead in other areas. A few days ago, the Company informed the public that it had signed a cooperation agreement with the renowned Institut Curie in Paris to test the breast cancer treatment T-DM1 Kadcyla ("Accum-T-DM1-ADC"), which has been optimized using Accum technology. Extensive studies in animal experiments with mice are to be developed.

Using Accum technology, Defence Therapeutics expects to shorten treatment duration with fewer side effects while increasing efficacy through targeted drug positioning. We regard both announcements as highly positive. According to the market research institute Kuick, the market for breast cancer therapies alone is expected to reach a volume of USD 20 billion by 2026. In addition, there is great potential in the area of Covid-19 fighting. However, Defence Therapeutics is still in the relatively early stages of development with its products. It remains exciting in any case.

Formycon - Despite good business figures and a positive news flow, the share is currently unable to break out to the upside

The share price of biosimilar pioneer Formycon seems to be tied to the EUR 60 mark with a rubber band. About a week ago, the Company published quite good financial figures in line with expectations, announced a renewed application for approval of its drug FYB201 and announced that it had found appropriate distribution partners in Teva Pharmaceuticals and Coherus. In addition, the Company announced that its previously unpartnered Covid-19 vaccine FYB207, which is based on a long-acting ACE2 immunoglobulin fusion protein, has received a EUR 12.7 million financial injection from the Free State of Bavaria as part of the "BayTherapie 2020" initiative. Development of the previously unpublished and unpartnered biosimilar candidate FY206 continues as planned. Based on all this data, analysts arrive at an average price target of around EUR 70. In their last update from the beginning of the month, the analysts from First Berlin even see EUR 78 as realistic. However, all this seems to make little impression on the stock market at present. Despite the positive news flow, there is currently no sign of an upward breakout.


So which biotech stock suits which type of investor? BioNTech's stock is already quite expensive, but we do not expect any slowdown in business in the near future. An investment in Defence Therapeutics is certainly riskier, but in the event of success, high returns await. Equally interesting for us is Formycon. It is unclear why the share price is currently stuck at EUR 60, and the positive newsflow should allow the share price to move upwards soon.


Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

21. October 2021 | 12:17 CET | by Stefan Feulner

Sartorius, Defence Therapeutics, QIAGEN - Still long potential

  • Biotechnology

Since the outbreak of the Corona pandemic, biotech and pharmaceutical shares have been among the top performers on the stock market. In addition to vaccine producers such as BioNTech and Pfizer, the share price of the US pharmaceutical Company Moderna also multiplied. Other winners included diagnostics companies and laboratory equipment suppliers, process technology specialists and manufacturers of biopharmaceuticals. Biopharmaceuticals promise enormous growth potential even after Corona, especially the market such as gene and cell therapies is growing dynamically at the moment.

Read

20. October 2021 | 11:04 CET | by Armin Schulz

Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?

  • Biotechnology

The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.

Read

18. October 2021 | 10:44 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Bayer: Where triple-digit returns beckon

  • Biotechnology

The pandemic is drawing to a close. Vaccination rates are high, and a new wave is - fortunately - not picking up speed. But in this environment, what is happening to many highly acclaimed pandemic stocks? Are vaccine manufacturers still interesting at the moment? We look at how the industry is faring and where opportunities can still be found.

Read